Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Keros Therapeutics to “strong sell”, while the broader analyst consensus remains “Hold” with an average price target of $20.50.
• KROS shares opened at $10.10, near their 52-week low of $9.69, and the company reported a quarterly loss of $1.45 per share—worse than analysts’ expected loss of $1.34.
• Institutional investors own 71.56% of the stock, although insiders sold 8,425 shares worth about $89,994 during the past quarter.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research report issued on Sunday.

Several other equities analysts have also commented on KROS. Wells Fargo & Company decreased their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating on the stock in a report on Tuesday, August 4th. Leerink Partners dropped their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a report on Tuesday, August 4th. Zacks Research downgraded shares of Keros Therapeutics from a "hold" rating to a "strong sell" rating in a report on Wednesday, July 29th. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Keros Therapeutics in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $20.50.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $10.10 on Friday. The firm has a market capitalization of $200.28 million, a price-to-earnings ratio of -2.73 and a beta of 0.99. Keros Therapeutics has a 1 year low of $9.69 and a 1 year high of $22.55. The business's 50 day moving average price is $10.63 and its 200-day moving average price is $12.10.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, sell-side analysts expect that Keros Therapeutics will post -5.16 earnings per share for the current year.

Insider Transactions at Keros Therapeutics

In other news, Director Julius Knowles sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the sale, the director owned 10,958 shares of the company's stock, valued at approximately $117,579.34. This represents a 19.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the firm's stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the transaction, the director directly owned 9,767 shares of the company's stock, valued at approximately $104,799.91. The trade was a 21.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 8,425 shares of company stock valued at $89,994. 12.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Keros Therapeutics in the second quarter worth $29,898,000. Vanguard Group Inc. raised its stake in shares of Keros Therapeutics by 3.3% in the third quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company's stock valued at $43,011,000 after acquiring an additional 87,129 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Keros Therapeutics by 26.6% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company's stock valued at $15,645,000 after acquiring an additional 161,336 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company's stock valued at $7,547,000 after purchasing an additional 205,022 shares during the period. Finally, Federated Hermes Inc. boosted its holdings in Keros Therapeutics by 27.3% in the fourth quarter. Federated Hermes Inc. now owns 654,724 shares of the company's stock valued at $13,330,000 after purchasing an additional 140,564 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source